Rafiee Reihaneh, Razmara Ehsan, Motavaf Mahsa, Mossahebi-Mohammadi Majid, Khajehsharifi Shima, Rouhollah Fatemeh, Babashah Sadegh
Department of Cellular and Molecular Sciences, Faculty of Advanced Sciences and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Department of Medical Genetics, Faculty of Medical Sciences, TarbiatModares University, Tehran, Iran.
J Cancer Res Ther. 2022 Dec;18(Supplement):S383-S390. doi: 10.4103/jcrt.JCRT_752_20.
Colorectal cancer (CRC) is one of the most common cancers worldwide. Although colonoscopy is considered as the "Gold Standard" technique to detect CRC, its application is invasive and cost incurred. Thus, noninvasive or minimally invasive approaches are of utmost importance. The aberrant expression of some microRNAs (miRNAs, miRs) has been suggested in association with CRC pathogenesis. This study aimed to validate if circulating serum miR-1229 and miR-1246 are diagnostic biomarkers for CRC.
Serum samples were isolated from 45 CRC patients and also 45 healthy controls (HC). The expression levels of circulating serum-derived miR-1229 and miR-1246 were evaluated by quantitative real-time polymerase chain reaction. Receiver operating characteristic (ROC) curves were constructed to evaluate the CRC diagnostic accuracy of selected miRNAs. Furthermore, the association of candidate miRNAs and clinicopathological characteristics were evaluated. Functional enrichment of the candidate miRNAs was applied using in silico tools.
The expression of miR-1229 and miR-1246 was significantly higher in CRC patients than HC (P < 0.0001) and also was found in association with lymph node metastasis (P < 0.05). We demonstrated a significant up-regulation of serum-derived miR-1246 in advanced tumor-node-metastasis stage III of CRC patients (P < 0.05). Areas under the ROC curve of miR-1229 and miR-1246 were 0.81 and 0.84, respectively (P < 0.0001).
We confirmed the capability of circulating serum miR-1229 and miR-1246 as novel diagnostic biomarkers for CRC.
结直肠癌（CRC）是全球最常见的癌症之一。尽管结肠镜检查被认为是检测CRC的“金标准”技术，但其应用具有侵入性且成本高昂。因此，非侵入性或微创方法至关重要。一些微小RNA（miRNA，miRs）的异常表达已被认为与CRC发病机制有关。本研究旨在验证循环血清miR-1229和miR-1246是否为CRC的诊断生物标志物。
从45例CRC患者和45例健康对照（HC）中分离血清样本。通过定量实时聚合酶链反应评估循环血清来源的miR-1229和miR-1246的表达水平。构建受试者工作特征（ROC）曲线以评估所选miRNA对CRC的诊断准确性。此外，评估候选miRNA与临床病理特征的相关性。使用计算机工具对候选miRNA进行功能富集分析。
CRC患者中miR-1229和miR-1246的表达明显高于HC（P < 0.0001），并且与淋巴结转移有关（P < 0.05）。我们证明CRC患者晚期肿瘤-淋巴结-转移III期血清来源的miR-1246显著上调（P < 0.05）。miR-1229和miR-1246的ROC曲线下面积分别为0.81和0.84（P < 0.0001）。
我们证实循环血清miR-1229和miR-1246作为CRC新型诊断生物标志物的能力。
